The tweet was deleted by the author.
But we saved everything 🙂.
Climb Bio, Inc. announced its sponsorship of the NephCure Patient and Youth Summits, aiming to bring patients, caregivers, researchers, and advocates together to foster collaboration and knowledge sharing in the rare kidney disease community.
The initiative underscores the company’s commitment to accelerating progress for those affected by rare kidney conditions. The summits are expected to provide a platform for learning, connecting, and developing new strategies to support patients and advance research.
Climb Bio, Inc. recently presented initial safety and platelet results from its Phase 1b/2a budoprutug trial in ITP at the EHA congress. The company also discussed its ongoing immunology strategy and future autoimmune research during a Jefferies fireside chat. These events reflect Climb Bio's active engagement in clinical development and research focused on rare diseases.